Our Next Big Medical Breakthrough? Forbes on Lexagene LXXGF 2019 Forbes article on LexaGene, wow!
This New Device’s Rapid Pathogen Identification May Be Our Next Big Medical Breakthrough
https://www.forbes.com/sites/jimvinoski/2019/12/10/this-new-devices-rapid-pathogen-identification-may-be-our-next-big-medical-breakthrough/?sh=7bbd35252f63
What if we had a piece of technology that could quickly detect and identify those nasty little creatures that cause so much heartache, illness and death, allowing fast diagnoses for illness prevention and treatment? LexaGene, a start-up in Beverly, Massachusetts, may have just that.
This was Dec 2019, now LexaGene is to market. And look at pic, they have made MiQLab smaller.
How rare that is, a nanocap geting covered by Forbes.
New article on it on Seeking Alpha: Is LexaGene The Perfect Stock?
Conclusion
The PCR medical testing sector is a wonderful business with very high stock market valuations and buyout valuations. It is recession resistant, in fact the best year ever for PCR was the recession of 2020. LexaGene's MiQLab is a breakthrough product in terms of cost, ease of use, and open access. Am expecting that the FDA will approve it in 2021 for human POC and that LexaGene will be able to generate multiple millions in revenue within a year. Believe that will result in a 10 bagger or better, which would be $8 a share. Can find nothing wrong with this company after studying it for a week. So the answer the question in the title, yes LexaGene is the perfect stock.
https://seekingalpha.com/instablog/535947-darp-research/5551692-is-lexagene-perfect-stock